SAN DIEGO, Jan. 2, 2019 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
that its chief executive officer, Brian
Lian, Ph.D., will deliver a corporate presentation at the
11th Annual Biotech Showcase™, being held
January 7-9, 2019 at the Hilton San
Francisco Union Square in San Francisco.
Details for this presentation are as follows:
- Biotech Showcase 2019 – webcast available
Time/Date: 11:30 a.m. PT on Monday, January
7, 2019
Location: Hilton San Francisco Union Square
Room: Yosemite C
To access the live webcast of Viking's presentation, please
visit "Webcasts & Presentations" within the News & Events
section of Viking's Investors page at www.vikingtherapeutics.com.
Additionally, a replay of the webcast will be available on the
Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics,
Inc. is a clinical-stage biopharmaceutical company focused on the
development of novel, first-in-class or best-in-class therapies for
metabolic and endocrine disorders. The company's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
small molecule selective thyroid hormone receptor beta agonist for
the treatment of lipid and metabolic disorders, including
non-alcoholic steatohepatitis (NASH). In a Phase 2 trial for
the treatment of non-alcoholic fatty liver disease and elevated
LDL-C, patients who received VK2809 demonstrated statistically
significant reductions in LDL-C and liver fat content. VK2809 was
shown to be safe and well-tolerated in the study. The company
is also developing VK0214, a small molecule selective thyroid
hormone receptor beta agonist for the treatment of X-linked
adrenoleukodystrophy. The company's other programs include
VK5211, an orally available, non-steroidal selective androgen
receptor modulator. In a Phase 2 trial in patients recovering
from hip fracture, patients who received VK5211 experienced
significant improvements in measures of lean body mass compared to
patients who received placebo. Other programs also include
VK0612, a first-in-class, orally available drug candidate in Phase
2 development for the treatment of type 2 diabetes as well as two
earlier-stage programs targeting metabolic diseases and
anemia. Viking holds exclusive worldwide rights to a
portfolio of five therapeutic programs, including those noted
above, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated.
Follow Viking on Twitter @Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-biotech-showcase-2019-300771590.html
SOURCE Viking Therapeutics, Inc.